Midazolam

Generic Name: Midazolam

Brand Names: Buccolam, Busulfex, Nayzilam, Seizalam

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₃ClFN_₃

CAS Number: 59467-70-8

Unique Ingredient Identifier: R60L0SM5BC

Background: Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...

Indication: Midazolam has different indications depending on its formulation by the FDA.

Nasal
...

Associated Conditions: Epileptic seizure, Status Epilepticus

Associated Therapies: Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy

Clinical Trials

Pro-Epileptic Effects of IV Ketamine

Phase 4

Active, not recruiting

Conditions: Epilepsy
Seizure

Interventions: Drug: Ketamine
Drug: Midazolam
Drug: Propofol

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-20

Lead Sponsor: Haseki Training and Research Hospital

Target Recruit Count: 300

Registration Number: NCT06741930

Locations: 🇹🇷
Haseki Training and Research Hospital, Istanbul, Turkey

Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine

Phase 4

Not yet recruiting

Conditions: Sedation During Bronchoscopy

Interventions: Drug: Propofol 1%
Drug: Midazolam
Drug: Pethidine

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Fondazione Andrea Cesalpino Arezzo ONLUS

Target Recruit Count: 530

Registration Number: NCT06736938

Locations: 🇮🇹
San Donato Hospital, Arezzo, Italy

Effect of Remazolam Besylate Combined with Remifentanil Analgesic Sedation on the Prognosis of Patients with Sepsis

Phase 4

Not yet recruiting

Conditions: Sepsis

Interventions: Drug: Midazolam
Drug: Remazolam besylate

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: First Affiliated Hospital of Ningbo University

Target Recruit Count: 100

Registration Number: NCT06731088

A Study of S-740792 in Healthy Adult Study Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: S-740792
Drug: Placebo
Drug: Midazolam

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-16

Lead Sponsor: Shionogi

Target Recruit Count: 116

Registration Number: NCT06724978

Locations: 🇺🇸
Fortrea Clinical Research Unit, Inc., Daytona Beach, Florida, United States

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: BI 3731579
Drug: Placebo matching BI 3731579
Drug: Midazolam

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT06716190

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Drug-Drug Interaction Study of Orforglipron (LY3502970) with Quinidine in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: Orforglipron
Drug: Midazolam
Drug: Quinidine

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT06704763

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States

The RECAP2 Study: Midazolam and Psilocybin

Phase 1

Not yet recruiting

Conditions: Psilocybin

Interventions: Drug: Psilocybin
Drug: Saline
Drug: Midazolam

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-26

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 60

Registration Number: NCT06692192

Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: Vamorolone
Drug: Midazolam

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Santhera Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT06689527

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Phase 1

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Amlitelimab
Drug: Midazolam
Drug: Caffeine
Drug: Metoprolol
Drug: Omeprazole
Drug: Warfarin

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT06686628

Locations: 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

Phase 1

Recruiting

Conditions: Healthy Study Participants

Interventions: Drug: midazolam
Drug: metformin
Drug: bupropion
Drug: fenfluramine HCl

First Posted Date: 2024-11-07

Last Posted Date: 2024-12-13

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 22

Registration Number: NCT06679413

Locations: 🇺🇸
Up0132 1001, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy